ES2191769T3 - Derivados 3-espiro-indolin-2-ona como ligandos de los receptores de la vasopresina y/o de la ocitocina. - Google Patents

Derivados 3-espiro-indolin-2-ona como ligandos de los receptores de la vasopresina y/o de la ocitocina.

Info

Publication number
ES2191769T3
ES2191769T3 ES96934967T ES96934967T ES2191769T3 ES 2191769 T3 ES2191769 T3 ES 2191769T3 ES 96934967 T ES96934967 T ES 96934967T ES 96934967 T ES96934967 T ES 96934967T ES 2191769 T3 ES2191769 T3 ES 2191769T3
Authority
ES
Spain
Prior art keywords
indolin
ona
receptors
derivatives
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96934967T
Other languages
English (en)
Spanish (es)
Inventor
Loic Foulon
Georges Garcia
Gal Claudine Serradeil-Le
Gerard Valette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2191769T3 publication Critical patent/ES2191769T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES96934967T 1995-10-24 1996-10-24 Derivados 3-espiro-indolin-2-ona como ligandos de los receptores de la vasopresina y/o de la ocitocina. Expired - Lifetime ES2191769T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512533A FR2740136B1 (fr) 1995-10-24 1995-10-24 Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
ES2191769T3 true ES2191769T3 (es) 2003-09-16

Family

ID=9483867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96934967T Expired - Lifetime ES2191769T3 (es) 1995-10-24 1996-10-24 Derivados 3-espiro-indolin-2-ona como ligandos de los receptores de la vasopresina y/o de la ocitocina.

Country Status (30)

Country Link
US (2) US5994350A (cg-RX-API-DMAC7.html)
EP (1) EP0873309B1 (cg-RX-API-DMAC7.html)
JP (2) JP3274471B2 (cg-RX-API-DMAC7.html)
KR (1) KR100298925B1 (cg-RX-API-DMAC7.html)
CN (1) CN1106384C (cg-RX-API-DMAC7.html)
AR (1) AR004225A1 (cg-RX-API-DMAC7.html)
AT (1) ATE229940T1 (cg-RX-API-DMAC7.html)
AU (1) AU715841B2 (cg-RX-API-DMAC7.html)
BR (1) BR9611198A (cg-RX-API-DMAC7.html)
CZ (1) CZ295585B6 (cg-RX-API-DMAC7.html)
DE (1) DE69625517T2 (cg-RX-API-DMAC7.html)
DK (1) DK0873309T3 (cg-RX-API-DMAC7.html)
EE (1) EE04433B1 (cg-RX-API-DMAC7.html)
ES (1) ES2191769T3 (cg-RX-API-DMAC7.html)
FR (1) FR2740136B1 (cg-RX-API-DMAC7.html)
HU (1) HUP9900331A3 (cg-RX-API-DMAC7.html)
IL (1) IL124002A (cg-RX-API-DMAC7.html)
IN (1) IN185328B (cg-RX-API-DMAC7.html)
IS (1) IS1949B (cg-RX-API-DMAC7.html)
MY (1) MY115864A (cg-RX-API-DMAC7.html)
NO (1) NO310974B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ320352A (cg-RX-API-DMAC7.html)
PL (1) PL187093B1 (cg-RX-API-DMAC7.html)
RU (1) RU2167864C2 (cg-RX-API-DMAC7.html)
SK (1) SK284546B6 (cg-RX-API-DMAC7.html)
TR (1) TR199800719T2 (cg-RX-API-DMAC7.html)
TW (1) TW474917B (cg-RX-API-DMAC7.html)
UA (1) UA59345C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997015556A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA968945B (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2775598A1 (fr) 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
HU225703B1 (en) * 1999-07-15 2007-06-28 Sanofi Aventis Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives
HUP9902374A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
HU225150B1 (en) * 1999-07-15 2006-07-28 Sanofi Aventis Novel process for producing 2-methoxy-4-(t-butylaminocarbonyl)-benzenesulfonyl chloride
HUP9902376A3 (en) 1999-07-15 2002-11-28 Sanofi Aventis Process for producing n-(1,1-dimethyl)-4-[[s'-ethoxi-4-cis-[2-(4-morpholino)-ethoxi]-2'-oxospiro[cyclohexane-1,3'-[3h]indole]-1'(2'h)yl]-sulfonyl]-3-methoxybenzamide and its salts
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
CA2425892A1 (en) * 2000-11-28 2003-04-11 Hiroyuki Koshio 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof
WO2002047679A2 (en) * 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US7498332B2 (en) 2001-02-14 2009-03-03 Duke University Therapy for cerebral vasospasm
CN1243736C (zh) * 2001-07-31 2006-03-01 赛诺菲-安万特公司 3－螺环己烷－1,3'－'3h吲哚满－2'－酮衍生物的制备方法
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
FR2874920B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one comme ligand des recepteurs de la vasopressine
FR2874921B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one, leur preparation et leur application en therapeutique
MX2007007103A (es) * 2004-12-13 2008-03-10 Lilly Co Eli Derivados espiro como inhibidores de lipoxigenasa.
EP1831197A2 (de) * 2004-12-31 2007-09-12 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
BRPI0719210A2 (pt) 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
JP2010522690A (ja) * 2006-10-12 2010-07-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド 三環式スピロオキシインドール誘導体および治療薬としてのその使用
EP2076514A1 (en) * 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
JP5570172B2 (ja) * 2008-10-08 2014-08-13 持田製薬株式会社 喫煙による循環機能不全の予防／改善または治療剤
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
MD4202C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbometoxi ai spiro[ciclopropan-oxindolilor]
MD4201C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbonitrilici ai spiro[ciclopropan-oxindolilor]
CN108191864A (zh) * 2013-03-08 2018-06-22 沃克哈特有限公司 制备氧代磺酰氧基[(哌啶羰基)-肼基羰基]二氮杂-双环辛烷的方法
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
MX9803269A (es) 1998-09-30
JP2001302631A (ja) 2001-10-31
DE69625517D1 (de) 2003-01-30
MY115864A (en) 2003-09-30
FR2740136A1 (fr) 1997-04-25
UA59345C2 (uk) 2003-09-15
HUP9900331A2 (hu) 1999-05-28
EP0873309A1 (fr) 1998-10-28
FR2740136B1 (fr) 1998-01-09
IL124002A (en) 2002-11-10
DK0873309T3 (da) 2003-03-17
EP0873309B1 (fr) 2002-12-18
TW474917B (en) 2002-02-01
PL326555A1 (en) 1998-09-28
CZ126798A3 (cs) 1998-08-12
HUP9900331A3 (en) 1999-11-29
JP3274471B2 (ja) 2002-04-15
WO1997015556A1 (fr) 1997-05-01
NZ320352A (en) 2000-01-28
KR100298925B1 (ko) 2001-09-06
AU7308096A (en) 1997-05-15
ATE229940T1 (de) 2003-01-15
EE04433B1 (et) 2005-02-15
ZA968945B (en) 1997-05-29
NO981817L (no) 1998-04-23
KR19990067056A (ko) 1999-08-16
TR199800719T2 (xx) 1998-08-21
RU2167864C2 (ru) 2001-05-27
IS1949B (is) 2004-10-13
NO981817D0 (no) 1998-04-23
BR9611198A (pt) 1999-04-06
AU715841B2 (en) 2000-02-10
CZ295585B6 (cs) 2005-08-17
IN185328B (cg-RX-API-DMAC7.html) 2000-12-30
SK49098A3 (en) 1998-09-09
AR004225A1 (es) 1998-11-04
CN1106384C (zh) 2003-04-23
SK284546B6 (sk) 2005-06-02
IS4714A (is) 1998-04-14
US6046341A (en) 2000-04-04
DE69625517T2 (de) 2003-09-11
HK1016596A1 (en) 1999-11-05
NO310974B1 (no) 2001-09-24
JPH11509232A (ja) 1999-08-17
CN1202886A (zh) 1998-12-23
EE9800151A (et) 1998-12-15
US5994350A (en) 1999-11-30
PL187093B1 (pl) 2004-05-31

Similar Documents

Publication Publication Date Title
ES2191769T3 (es) Derivados 3-espiro-indolin-2-ona como ligandos de los receptores de la vasopresina y/o de la ocitocina.
BR9711444A (pt) Derivados de adenosina substituìdos por heterocìclico n6.
CY1110633T1 (el) Τροποποιηση αντιθετης φορας της εκφρασης σουρβιβινης
DE69603240D1 (de) Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
HN1996000017A (es) Isotiazolonas
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DE69720732D1 (de) Substituierte Triazolo-Pyridazin-Derivate als Liganden von GABA-Rezeptoren
DE69821132T2 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE69428536D1 (de) A3 -adenosin -rezeptor agonisten
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
ES2188888T3 (es) Derivados morfinoides 8ii) con condensados con heterociclos.
PT915974E (pt) Ligandos de receptores de tie-2 modificados
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
ATE148114T1 (de) Fluor substituierte benzocycloheptapyridine, zusammensetzungen und verfahren zur verwendung derselben als antihistaminische verbindungen
ATE294152T1 (de) Substituierte tetrahydro-naphtaline und analoge verbindungen
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
DE69903333D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
CO5460266A1 (es) Novedosos analogos de la somatostatina
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
NO20002408L (no) 5-HT1F antagonister
ATE286123T1 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
ES2181015T3 (es) P-trifluormetilfeniluracilos substituidos.